Table 2.
Treatment history among patients with ankylosing spondylitis (AS) who had been receiving secukinumab for ≥ 3 months
| Patients with AS (N = 200) | |
|---|---|
| Duration of secukinumab treatment for AS, n (%) | |
| 3–4 months | 33 (16.5) |
| 5–6 months | 39 (19.5) |
| 7–9 months | 35 (17.5) |
| 10–12 months | 36 (18.0) |
| > 12 months | 57 (28.5) |
| Approximate time between stopping previous treatment and initiating secukinumab, n (%)a | |
| < 1 week | 21 (10.9) |
| 1 week to < 1 month | 45 (23.3) |
| 1 to < 2 months | 35 (18.1) |
| 2 to < 3 months | 36 (18.7) |
| 3–4 months | 30 (15.5) |
| ≥ 5 months | 26 (13.5) |
| Main reason for stopping previous treatment, n (%)a | |
| Lack/loss of efficacy/effectiveness | 49 (25.4) |
| Unwanted side effects | 44 (22.8) |
| Anxiety/fear of injections/needles | 28 (14.5) |
| Co-pay too high | 21 (10.9) |
| Other reasonsb | 51 (26.4) |
| Past medication use, n (%) | |
| Over-the-counter NSAID | 174 (87.0) |
| Prescription NSAID | 169 (84.5) |
| Steroid | 106 (53.0) |
| Physical therapy | 144 (72.0) |
| Biologic | 173 (86.5) |
| Never taken any nonbiologic treatment | 6 (3.0) |
| Never taken any biologic treatment | 27 (13.5) |
NSAID nonsteroidal anti-inflammatory drug
aAmong patients who received a previous treatment for AS (n = 193)
bOther reasons include “insurance would not pay,” “treatment was not easy or convenient to take,” “injection/infusion was painful,” “frequency of dosing was too high,” “number of required physician visits was too high,” “number of required blood tests was too high,” and “other”